{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "marketState": "PRE", "exchange": "NCM", "regularMarketChangePercent": 1.7045438, "regularMarketPrice": 0.895, "firstTradeDateMilliseconds": 1539869400000, "priceHint": 4, "earningsTimestamp": 1683921600, "earningsTimestampStart": 1692010800, "earningsTimestampEnd": 1692356400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.45, "epsForward": -0.41, "epsCurrentYear": -0.51, "priceEpsCurrentYear": -1.754902, "sharesOutstanding": 77494800, "bookValue": 0.043, "fiftyDayAverage": 1.0894, "fiftyDayAverageChange": -0.19440007, "fiftyDayAverageChangePercent": -0.1784469, "twoHundredDayAverage": 1.6349, "twoHundredDayAverageChange": -0.7399, "twoHundredDayAverageChangePercent": -0.4525659, "marketCap": 71091728, "forwardPE": -2.182927, "priceToBook": 20.813951, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Clene Nanomedicine Inc.", "nameChangeDate": "2023-05-15", "averageAnalystRating": "1.9 - Buy", "tradeable": false, "cryptoTradeable": false, "shortName": "Clene Inc.", "longName": "Clene Inc.", "messageBoardId": "finmb_339429732", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "preMarketChange": 0.02670002, "preMarketChangePercent": 2.9832425, "preMarketTime": 1684226700, "preMarketPrice": 0.9217, "regularMarketChange": 0.014999986, "regularMarketTime": 1684180756, "regularMarketDayHigh": 0.9, "regularMarketDayRange": "0.86 - 0.9", "regularMarketDayLow": 0.86, "regularMarketVolume": 46211, "regularMarketPreviousClose": 0.88, "bid": 0.0, "ask": 0.0, "bidSize": 10, "askSize": 18, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 0.88, "averageDailyVolume3Month": 344215, "averageDailyVolume10Day": 76210, "fiftyTwoWeekLowChange": 0.044999957, "fiftyTwoWeekLowChangePercent": 0.052941125, "fiftyTwoWeekRange": "0.85 - 5.13", "fiftyTwoWeekHighChange": -4.235, "fiftyTwoWeekHighChangePercent": -0.8255361, "fiftyTwoWeekLow": 0.85, "fiftyTwoWeekHigh": 5.13, "displayName": "Clene", "symbol": "CLNN"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "6550 South Millrock Drive", "address2": "Suite G50", "city": "Salt Lake City", "state": "UT", "zip": "84121", "country": "United States", "phone": "801 676 9695", "website": "https://clene.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 75, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert  Etherington MBA", "age": 55, "title": "CEO, Pres & Director", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 590982, "fmt": "590.98k", "longFmt": "590,982"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1130337, "fmt": "1.13M", "longFmt": "1,130,337"}}, {"maxAge": 1, "name": "Mr. Morgan R. Brown CPA, CPA, M.B.A., MBA", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 374046, "fmt": "374.05k", "longFmt": "374,046"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mark G. Mortenson ESQ.", "age": 64, "title": "Chief Science Officer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 482977, "fmt": "482.98k", "longFmt": "482,977"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 584464, "fmt": "584.46k", "longFmt": "584,464"}}, {"maxAge": 1, "name": "Mr. Jerry  Miraglia J.D.", "title": "Gen. Counsel & Corp. Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Michael T. Hotchkin", "title": "Chief Devel. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Mary Anne Mcneil", "title": "Head of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Benjamin M. Greenberg M.D., M.H.S.", "title": "Head of Medical", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}